Palvella Therapeutics (PVLA) Enterprise Value (2013 - 2026)
Palvella Therapeutics' (PVLA) quarterly Enterprise Value came in at -$261.9 million in Q1 2026, down 246.25% year-on-year from $179.0 million in Q1 2025, and down 351.61% on a QoQ basis from -$58.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Enterprise Value (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Enterprise Value data on file, last reported at -$261.9 million in Q1 2026.
- On a quarterly basis, Enterprise Value fell 246.25% year-over-year to -$261.9 million in Q1 2026; TTM through Mar 2026 was -$261.9 million, a 246.25% decrease from a year earlier, with the FY2025 full-year figure at -$58.0 million, up 30.65% from the prior year.
- Enterprise Value for Q1 2026 stood at -$261.9 million, down from -$58.0 million in the prior quarter.
- Over the last five years, Enterprise Value for PVLA reached as high as -$6.2 million in Q1 2024 and fell as low as -$261.9 million in Q1 2026.
- Historically, Enterprise Value has averaged -$69.1 million across 5 years, with a median of -$63.6 million in 2025.
- Across the five-year window, Enterprise Value surged 89.05% in 2024 and sank 1110.4% in 2025, its largest moves.
- Year by year, Enterprise Value stood at -$59.2 million in 2022, then surged by 72.42% to -$16.3 million in 2023, then sank by 412.27% to -$83.6 million in 2024, then surged by 30.65% to -$58.0 million in 2025, then plunged by 351.61% to -$261.9 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$261.9 million in Q1 2026, -$58.0 million in Q4 2025, and -$63.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | -261.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -261.85 Mn |
| Dec 31, 2025 | -57.98 Mn |
| Sep 30, 2025 | -63.57 Mn |
| Jun 30, 2025 | -70.43 Mn |
| Mar 31, 2025 | -75.63 Mn |
| Dec 31, 2024 | -83.60 Mn |
| Sep 30, 2024 | -14.21 Mn |
| Jun 30, 2024 | -14.54 Mn |
| Mar 31, 2024 | -6.25 Mn |
| Dec 31, 2023 | -16.32 Mn |
| Sep 30, 2023 | -56.72 Mn |
| Jun 30, 2023 | -64.84 Mn |
| Mar 31, 2023 | -57.04 Mn |
| Dec 31, 2022 | -59.17 Mn |
| Sep 30, 2022 | -91.20 Mn |
| Jun 30, 2022 | -80.94 Mn |
| Mar 31, 2022 | -100.27 Mn |
| Dec 31, 2021 | -117.76 Mn |
| Sep 30, 2021 | -34.90 Mn |
| Jun 30, 2021 | -91.80 Mn |